Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: Results from the national health and nutrition examination survey (NHANES), 2003-2006

Mayo Clinic Proceedings

Volumn 88, Issue 1, 2013, Pages 11-21

  Loprinzi, Paul D ^a   Kohli, Manish ^b  

^a BELLARMINE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; C REACTIVE PROTEIN; COTININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN;

ACCELEROMETER; ADULT; AGE; ALCOHOL CONSUMPTION; BASOPHIL; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIETARY FIBER; DRUG USE; EDUCATION; EOSINOPHIL COUNT; ETHNICITY; FAT INTAKE; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; INCOME; LEUKOCYTE COUNT; MALE; MARRIAGE; NORMAL HUMAN; PHYSICAL ACTIVITY; POVERTY; PROSTATE SPECIFIC ANTIGEN BLOOD LEVEL; PROTEIN INTAKE; RACE; REVIEW; SEDENTARY LIFESTYLE; UNITED STATES; VITAMIN INTAKE;

EID: 84872943040     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.10.012     Document Type: Article

References (51)

1. Loprinzi PD, Cardinal BJ, Smit E, Winters-Stone K. Physical activity and breast cancer risk. J Exerc Sci Fitness. 2012;10(1):1-7.
2. Physical activity decreases cancer risk: exercise may help prevent the development of certain cancers, notably colon and breast, numerous studies show. Duke Med Health News. 2008;14(5):9-10.
3. Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med. 2008;42(8):636-647.
4. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009; 100(4):611-616.
5. Loprinzi PD, Cardinal BJ, Winters-Stone K, Smit E, Loprinzi CL. Physical activity and the risk of breast cancer recurrence: a literature review. Oncol Nurs Forum. 2012;39(3):269-274.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62(1):10-29.
7. Friedenreich CM, Thune I. A review of physical activity and prostate cancer risk. Cancer Causes Control. 2001;12(5):461-475.
8. Drudge-Coates L, Turner B. Prostate cancer overview. Part 1: non-metastatic disease. Br J Nurs. 2012;21(9):S23-S28.
9. Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao G. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev. 2008;17(9):2467-2472.
10. Andriole GL, Crawford ED, Grubb RL III, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
11. published correction appears in N Engl J Med. 2009;360:1797
12. Schröder FH, Hugosson J, Roobol MJ, et al ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
13. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106(2):320-328.
14. Shephard RJ. Limits to the measurement of habitual physical activity by questionnaires. Br J Sports Med. 2003;37(3):197-206; discussion 206.
15. Owen N, Sparling PB, Healy GN, Dunstan DW, Matthews CE. Sedentary behavior: emerging evidence for a new health risk. Mayo Clin Proc. 2010;85(12):1138-1141.
16. Owen N, Healy GN, Matthews CE, Dunstan DW. Too much sitting: the population health science of sedentary behavior. Exerc Sport Sci Rev. 2010;38(3):105-113.
17. Chen KY, Bassett DR Jr. The technology of accelerometrybased activity monitors: current and future. Med Sci Sports Exerc. 2005;37(11, suppl):S490-S500.
18. Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent in sedentary behaviors in the United States, 2003-2004. Am J Epidemiol. 2008;167(7):875-881.
19. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40:181-188.
20. Tucker JM, Welk GJ, Beyler NK. Physical activity in U.S.: adults compliance with the Physical Activity Guidelines for Americans. Am J Prev Med. 2011;40(4):454-461.
21. Luboldt HJ, Schindler JF, Rubben H. Age-specific reference ranges for prostate-specific antigen as a marker for prostate cancer. EAU-EBU Update Series. 2007;5:38-48.
22. Moshfegh AJ, Baer D, Cleveland L, et al. Validation of reported energy intakes in 24-hour dietary recalls using USDA automated multiple-pass method [abstract]. FASEB J. 2003;17(4):A281.
23. Rhodes DG, Moshfegh A, Cleveland L, et al. Accuracy of 24 hour dietary recalls: preliminary results from USDA AMPM Validation Study [abstract]. FASEB J. 2004;18(4):A111.
24. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010;28(25):3951-3957.
25. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care. 2010;33(suppl 1):S3.
26. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
27. National Health and Nutrition Examination Survey: Laboratory Procedures Manual. Complete Blood Count. http://www.cdc. gov/nchs/data/nhanes/nhanes-03-04/ l25-c-met-complete- blood-count.pdf. Accessed November 28, 2012.
28. Lau C-C, Kuk F. Enough is enough: a primer on power analysis in study designs. Hearing Journal. 2011;64(4):30-39.
29. Wood N. The Health Project Book: a Handbook for New Researchers in the Field of Health. London, UK: Routledge; 2001.
30. Carroll KK. Obesity as a risk factor for certain types of cancer. Lipids. 1998;33(11):1055-1059.
31. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006;4: CD003817.
32. Wallner LP, Morgenstern H, McGree ME, et al. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev. 2011;20(3):501-508.
33. Tulloch-Reid MK, Aiken WD, Morrison BF, et al. Body mass index and prostate specific antigen levels in Jamaican men. West Indian Med J. 2011;60(3):316-321.
34. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000;17(3):445-451.
35. Nieman DC. Exercise immunology: practical applications. Int J Sports Med. 1997;18(suppl 1):S91-S100.
36. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Design. 2012; 18(26):3831-3852.
37. Loprinzi P, Cardinal B, Crespo C, et al. Objectively measured physical activity and C-reactive protein: National Health and Nutrition Examination Survey 2003-2004. Scand J Med Sci Sports. In press.
38. Ji LL. Exercise and oxidative stress: role of the cellular antioxidant systems. Exerc Sport Sci Rev. 1995;23:135-166.
39. Feig DI, Reid TM, Loeb LA. Reactive oxygen species in tumorigenesis. Cancer Res. 1994;54(7, suppl):1890s-1894s.
40. Tremblay MS, Colley RC, Saunders TJ, Healy GN, Owen N. Physiological and health implications of a sedentary lifestyle. Appl Physiol Nutr Metab. 2010;35(6):725-740.
41. Marshall SJ, Ramirez E. Reducing sedentary behavior: a new paradigm in physical activity promotion. Am J Lifestyle Med. 2011;5:518-530.
42. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011;22(11):1545-1552.
43. Ahmed FS, Borrell LN, Spencer BA. Health risk behaviors and prostate specific antigen awareness among men in California. J Urol. 2008;180(2):658-662; discussion 662.
44. Loprinzi PD, Lee H, Cardinal BJ, Crespo C, Andersen R, Smit E. The relationship of Actigraph accelerometer cut-points for estimating physical activity with selected health outcomes: results from NHANES 2003-06. Res Q Exerc Sport. 2012;83:422-430.
45. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771.
46. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
47. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
48. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
49. published correction appears inNEngl J Med. 2004;351:1470
50. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012;30(24):3020-3025.
51. American Urological Association. Prostate Specific Antigen Best Practice Statement, 2009. http://www.auanet.org/content/ clinical-practice-guidelines/ clinical-guidelines.cfm#2. Accessed September 26, 2012.